Open Actively Recruiting

Registry for Participants With Short Bowel Syndrome

About

Brief Summary

This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for participants with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in participants with SBS. SBS participants treated and not treated with teduglutide will be enrolled.

Study Type
observational_patient_registry
Phase
N/A

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
N/A
Maximum Age
N/A

Inclusion Criteria:

  • Male and female participants, of any age, with a diagnosis of short bowel syndrome (SBS).
  • Signed informed consent and medical records release by the participant or a legally acceptable representative
  • Participants who have never received teduglutide treatment must be on parenteral nutrition (PN)/intravenous (IV) fluids support for at least 6 months at the time of enrollment.

Exclusion criteria:

  • Participants currently participating in a blinded clinical trial or their extension studies.
  • Participants who have never been on PN/IV support.
  • Participants who are currently or previously exposed to any Glucagon-like peptide 2 (GLP-2) analogs other than teduglutide.

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
18-000700
Category
Oncology
Surgery
Contact
Susan Feist
Location
  • UCLA Westwood
For Providers
NCT No.
NCT01990040
For detailed technical eligibility, visit ClinicalTrials.gov.